Related references
Note: Only part of the references are listed.Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
Elizabeth Dudnik et al.
LUNG CANCER (2018)
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Theodore S. Nowicki et al.
CANCER JOURNAL (2018)
Immunotherapy: a new standard of care in thoracic malignancies?
Adrien Costantini et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Understanding Subset Diversity in T Cell Memory
Stephen C. Jameson et al.
IMMUNITY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Yannick Simoni et al.
NATURE (2018)
Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice
Joanna Domagala-Kulawik
ADVANCES IN RESPIRATORY MEDICINE (2018)
Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans
Iwona Kwiecien et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer
Elena Tassi et al.
CANCER RESEARCH (2017)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
Oscar Arrieta et al.
ONCOTARGET (2017)
Personalised medicine for nonsmall cell lung cancer
Celine Mascaux et al.
EUROPEAN RESPIRATORY REVIEW (2017)
Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer
Jacek Rutkowski et al.
CELLULAR IMMUNOLOGY (2017)
How to evaluate the immune status of lung cancer patients before immunotherapy
Joanna Domagala-Kulawik et al.
BREATHE (2017)
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Khinh Ranh Voong et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
CD4-/CD25high/FoxP3+/CD127-regulatory T cells in bronchoalveolar lavage fluid of lung cancer patients
Iwona Osinska et al.
HUMAN IMMUNOLOGY (2016)
Genetic and Epigenetic Regulation of PD-1 Expression
Alexander P. R. Bally et al.
JOURNAL OF IMMUNOLOGY (2016)
SnapShot: T Cell Exhaustion
Kristen E. Pauken et al.
CELL (2015)
CD8+ CD103+ Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
Faycal Djenidi et al.
JOURNAL OF IMMUNOLOGY (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Confusing signals: Recent progress in CTLA-4 biology
Lucy S. K. Walker et al.
TRENDS IN IMMUNOLOGY (2015)
High CTLA-4 Expression on Th17 Cells Results in Increased Sensitivity to CTLA-4 Coinhibition and Resistance to Belatacept
S. M. Krummey et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
Kayoko Waki et al.
CANCER SCIENCE (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Mechanisms of immune response regulation in lung cancer
Joanna Domagala-Kulawik et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2014)
Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer
Joachim G. Aerts et al.
CANCER RESEARCH (2013)
Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer
T. A. Zikos et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Resident Memory T Cells (TRM) Are Abundant in Human Lung: Diversity, Function, and Antigen Specificity
Rahul Purwar et al.
PLOS ONE (2011)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
CTLA-4 co-receptor impacts on the function of Treg and CD8(+) T-cell subsets
Christopher E. Rudd
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology
David M. Sansom et al.
IMMUNOLOGICAL REVIEWS (2006)
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells
XB Wang et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
T-cell subtypes in bronchoalveolar lavage fluid and in peripheral blood from patients with primary lung cancer
J Domagala-Kulawik et al.
DIAGNOSTIC CYTOPATHOLOGY (2001)
Regulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cells
T Iida et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
